Feb. 21, 2018 3pm EST
Presenter: Dwight Tapp, BSc, PhD, MBA, CCRP, CECP, FACHE
Director of US Medical Affairs, Piramal Imaging
In this session, Dr. Tapp will review the preliminary, interim results from the recently closed CMS Coverage with Evidence Development study – “Imaging Dementia – Evidence for Amyloid Scanning” (IDEAS). He will also illustrate the primary indications and utilization of amyloid imaging, in particular with Neuraceq (F18 florbetaben injection), including risks and limitations of the diagnostic test. Finally, he will detail technical quality assessment for these scans, including common sources of error and image quality assessment and provide an overview of the role and impact of biomarkers in the early diagnosis, differential diagnosis, and follow-up of neurodegenerative disorders.